2017-09-06

SciBase presents the next generation Nevisense and a new type of electrode for the evaluation of New Applications

SciBase presents a new generation of its Nevisense device for early detection of malignant melanoma. The new Nevisense includes improvements in both software and hardware with the aim of streamlining the EIS measurement process. In addition, SciBase presents software and a new type of electrode which transform Nevisense into an impedance measurement platform for the evaluation of new clinical indications such as non-melanoma skin cancer.

The new Nevisense contains a number of new features aimed at improving the user experience and better integrating Nevisense into daily clinical workflow.

The next generation Nevisense includes the following:

- Intelligent guidance and user feedback built into the device based on AI (artificial intelligence), an improved patient archive and a storage capacity increased to over 1,000 patients
- New hardware with image management functionality, wifi connectivity and import of digital dermoscopy images
- Integration with Dermoscan's new EIS-compatible software for DermoGenius Ultra, which simplifies workflow with the aim of increasing usage of Nevisense

New electrodes open up the potential of new applications
In addition to the upgrades of the Nevisense software and hardware, SciBase presents a new type of electrode. The new 'flat' electrode does not have the same type of pins as the Nevisense electrode for melanoma, making it more suitable for the investigation of other skin disorders using electrical impedance. These include, for example, other types of skin cancer or atopic dermatitis.

- This product update is a major step for SciBase because we are expanding the market we can address in the future. We are redefining Nevisense from being an instrument used solely to detect melanoma to a platform that can potentially be used in several areas within Dermatology, "says Simon Grant, CEO of SciBase.

The update consists of three important parts. Firstly, SciBase have improved the Nevisense software so that it is optimised for the newly upgraded hardware. The main aim is to provide better guidance throughout the measurement process. The updates also improve overall user-friendliness, which is especially important for new or non-frequent users. The second area is a number of features for evaluating new clinical indications. This means that Nevisense becomes a platform for impedance measurement with different electrode and measurement options. Finally, SciBase have completed the integration with DermoGenius Ultra and the complete solution will be launched at two congresses in Germany during September.

For further information please visit www.scibase.com or contact:
Simon Grant, CEO
Tel: +46 72 887 43 99
E-mail: simon.grant@scibase.com

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB"). Avanza is the certified advisor. Further information is available on www.scibase.com.